%0 Journal Article
%T Effect of Combination therapy of Desmopressin and Docetaxel on prostate cancer cell DU145 proliferation, migration and growth
%A Azik Hoffman
%A Domenica Roberto
%A Hiroshi Sasaki
%A Laurence Klotz
%A Michelle J Mayer
%A Vasundara Venkateswaran
%J -
%D 2016
%R https://doi.org/10.18314/gjct.v2i1.100
%X Background: This study was designed to assess the efficacy of the combination of Desmopressin and Docetaxel for prostate cancer. Desmopressin has been demonstrated to inhibit tumor progression and metastasis in in vitro and in vivo models of breast cancer. Docetaxel, an anti-mitotic chemotherapeutic agent, is widely used for the treatment of castration resistant prostate cancer. However, it is associated with adverse effects and eventual drug resistance. This is the first report on the effect of combining Desmopressin and Docetaxel in prostate cancer, both in vitro and in vivo
%U https://www.gratisoa.org/journals/index.php/GJCT/article/view/100